Patent Licensing Basics

Patent licenses vary by exclusivity, scope, and rights transferred: EXCLUSIVE LICENSE: the licensee is the ONLY entity (including the licensor/patent owner) that has the right to practice the patent in the licensed field; the patent owner cannot use the patent in the licensed field during the exclusive license term; the most valuable type of license from the licensee's perspective; STANDING TO SUE: an exclusive licensee generally has standing to bring patent infringement suits, either alone or by joining the patent owner; Waterman v. Mackenzie (S.Ct. 1891): exclusive licensee has full title to the right and can sue for infringement; the patent owner must be joined as an indispensable party in most circuits (or consent to the suit) unless the exclusive licensee has ALL substantial rights; NON-EXCLUSIVE LICENSE: the licensor can grant the same license to multiple licensees, including the patent owner's right to practice; common in cross-licensing; technology access agreements; open licensing; generally more valuable to licensor (can maximize royalty income from many licensees); licensee takes on more competitive risk (multiple licensees can compete with the same technology); standing to sue: a non-exclusive licensee generally CANNOT sue for patent infringement (lacks constitutional standing — no proprietary interest in the patent); SOLE LICENSE: a non-exclusive license where the licensor agrees not to license others (but retains its own right to practice); different from exclusive: licensor can still use the technology; just won't license competitors; SUBLICENSABLE LICENSE: a license that grants the licensee permission to grant sublicenses to third parties; important in technology transfer where the licensee will incorporate the technology into products sold through distributors or to customers who need sublicenses to use the product; FIELD-OF-USE RESTRICTED LICENSE: the license is limited to specific fields (pharmaceutical; consumer; government use only); the licensee cannot use the patent outside the defined field; common in university licensing and multi-market technology.

Patent license royalty structures vary based on the parties' commercial needs: RUNNING ROYALTIES (most common): royalty calculated as a percentage of net sales of licensed products; EXAMPLE: 3% of net sales of any product incorporating the patented technology; ADVANTAGES: aligns incentives (licensor benefits when licensee is successful); lower upfront cost for licensee; risk-sharing; DISADVANTAGES: requires audit rights and compliance monitoring; royalty base definition can be contested; ROYALTY BASE: the calculation base for running royalties: usually net sales (sales minus returns; discounts; freight); IMPORTANT: must specify whether the base is (a) total product price, (b) price of the component incorporating the patent, or (c) smallest unit embodying the patent; post-Lucent and SSPPU principles apply to avoid overvaluation; LUMP SUM (PAID-UP) LICENSE: single upfront payment for a fully paid-up license; no ongoing royalty obligations; ADVANTAGES: eliminates audit risk; certainty for both parties; administrative simplicity; DISADVANTAGES: licensor loses upside if licensee is more successful than anticipated; higher upfront cost for licensee; HYBRID: combination of upfront fee + running royalties; common structure: upfront license execution fee + running royalty percentage; MILESTONE-BASED: payments tied to development or commercial milestones (regulatory approval; first commercial sale; sales volume thresholds); common in pharmaceutical licensing agreements; MINIMUM ANNUAL ROYALTIES: minimum guaranteed royalty per year regardless of actual sales; ensures the licensor receives minimum compensation even if the licensee underperforms or fails to commercialize; can trigger exclusive license reversion to non-exclusive if minimums are not met; STEPPED ROYALTIES: royalty rate decreases as sales volume increases (rewards high-volume commercial success); or increases as sales increase (protects small licensees during ramp-up); MOST-FAVORED-NATION (MFN) CLAUSE: if the licensor grants a lower royalty rate to any other licensee, the MFN licensee gets the same lower rate; protects licensee against preferential treatment of competitors.

Key boilerplate provisions that significantly affect license value: GRANT-BACK CLAUSES: a provision requiring the licensee to license back to the licensor any improvements to the licensed technology; EXCLUSIVE GRANT-BACK: licensee must exclusively license all improvements to licensor; PROBLEMATIC: this is potentially patent misuse (the licensor extends control beyond its patent to future improvements); courts scrutinize exclusive grant-backs for anticompetitive effect; NON-EXCLUSIVE GRANT-BACK: licensee must grant a non-exclusive license for improvements to licensor; GENERALLY ACCEPTABLE: non-exclusive grant-backs are standard and not considered misuse; the licensor gets access to improvements but the licensee remains free to commercialize them; REACH-THROUGH ROYALTIES: (in research tool licensing) royalties on downstream products developed using the licensed research tool; controversial; can be oppressive in pharmaceutical licensing; SUBLICENSE PROVISIONS: whether the licensee can grant sublicenses to third parties; WITHOUT EXPLICIT GRANT: the licensee cannot sublicense (Rite-Hite v. Kelley); the license is personal to the original licensee; PASS-THROUGH OBLIGATIONS: if sublicensing is permitted, the licensor may require that: sublicenses be in writing; sublicensees be bound by key license restrictions (e.g., field of use; territory; non-disparagement); copies of sublicenses be provided to licensor; AUDIT RIGHTS: the licensor's contractual right to audit the licensee's records to verify royalty accuracy; standard provision in running royalty agreements; AUDIT FREQUENCY: typically once per year; AUDIT SCOPE: books and records relating to royalty-bearing sales; AUDIT PAYMENT: shortfall + interest; often: licensee pays audit costs if shortfall exceeds 5-10% of reported royalties; ROYALTY REPORTS: licensee provides regular reports (quarterly; annual) with royalty calculations; RECORD RETENTION: licensee must maintain records for X years (typically 3-5) for audit purposes.

License term and termination conditions are critical to both parties: LICENSE TERM: typically: life of the patent (all patents in the licensed portfolio expire); definite period (3-5 years with renewal options); IMPORTANT: royalties cannot be collected after all licensed patents expire (Brulotte v. Thys); term of agreement can extend beyond patent expiration but royalty obligation must end; EXCLUSIVITY CARVE-OUTS: even in an 'exclusive' license, the licensor may retain rights to: practice the patent for its own internal purposes (not commercial competition); grant licenses for government use (required by 28 U.S.C. § 1498); grant licenses for academic or non-commercial research; grant licenses to affiliates; REVERSION PROVISIONS: conditions under which exclusivity reverts to non-exclusive (or the license terminates): failure to meet minimum annual royalties; failure to achieve specific commercial milestones; failure to obtain regulatory approval by a specified date; bankruptcy of the licensee; TERMINATION RIGHTS: FOR CAUSE: material breach (non-payment; non-reporting; breach of field restrictions); licensee challenges patent validity (anti-challenge clauses; see below); licensee's insolvency; FOR CONVENIENCE: either party can terminate on notice (licensor typically cannot terminate without cause in an exclusive license); ANTI-CHALLENGE CLAUSES: some licenses prohibit licensees from challenging the licensed patent's validity (disparagement clause); ENFORCEABILITY: courts have split on whether anti-challenge clauses are enforceable; MedImmune v. Genentech (S.Ct. 2007): a licensee in good standing CAN bring a declaratory judgment action challenging the licensed patent; the licensor cannot terminate the license simply because the licensee filed a DJ action; NOTE: while DJ actions are available, some contracts provide for license termination upon challenge — these termination clauses may be enforceable even if the anti-challenge clause is not; LIQUIDATED DAMAGES: some licenses specify damages for breach; must not be a penalty (disproportionate to anticipated harm) to be enforceable.

Key negotiation points and hidden risks in patent licensing: FOR LICENSORS: ROYALTY BASE DEFINITION: define 'net sales' precisely; specify what deductions are permitted (returns up to X%; discounts up to X%; freight; taxes); vague definitions lead to disputes; FIELD OF USE: define the field narrowly enough to allow licensing the patent in other fields; a field-of-use license in 'medical devices' is much narrower than 'all uses'; GRANT-BACK SCOPE: what counts as an 'improvement'?; must it be based on the licensed patent?; does it include the licensee's own innovations that are merely combinable with the licensed technology?; MINIMUM ROYALTIES AND DILIGENCE: ensure the licensee actually commercializes; minimum annual royalties create economic incentive; milestone provisions create legal obligation; MOST-FAVORED-NATION CLAUSE RISKS: if MFN is granted to multiple licensees, a single favorable settlement with one licensee can trigger MFN adjustments for all — potentially wiping out royalty income; FOR LICENSEES: PATENT VALIDITY RISK: licensing a patent does not guarantee the patent is valid; should include representations that the licensor knows of no prior art that would invalidate the patent; consider invalidity research before execution; SCOPE OF THE LICENSE: ensure the field of use covers the actual commercial applications; overly narrow field definitions can leave commercial opportunities uncovered; SUBLICENSE RIGHTS: essential if the licensee's products will be resold through channel partners who need protection; RIGHT TO IMPROVEMENTS: does the licensee get access to improvements made by the licensor to the licensed technology?; important if the patent covers a technology platform that will evolve; PATENT MARKING OBLIGATIONS: does the licensor or licensee bear the obligation to mark licensed products?; failure to mark limits damages recovery against infringers (§ 287); MOST COMMON DISPUTES: royalty base calculation; what constitutes a 'licensed product'; audit findings and shortfalls; field-of-use scope disputes; improvements ownership; sublicense royalty accounting.